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Drugs must dissolve upon administration to have a therapeutic effect. 
Nowadays, most new drug candidates are poorly water-soluble, which makes 
this solubility issue a significant global challenge. Solubilization can be 
enhanced using formulation-based solutions, particle size reduction, salt 
formation, prodrugs or amorphization of the drug. This thesis concerns the 
last approach, amorphization. Unlike highly ordered crystalline materials, 
amorphous materials lack long range order. This leads to amorphous materials 
having greater molecular mobility and free energy, and consequently 
solubility, than their crystalline counterparts. However, the solubility benefits 
of the amorphous form come with a price, since the thermodynamic instability 
of amorphous materials means they tend to crystallize. 
Pharmaceutical products need to be sufficiently physically and chemically 
stable throughout their entire shelf life to ensure their efficacy and safety. In 
the case of amorphous drugs, there are still many aspects about crystallization 
that are not fully understood. The aim of the thesis was to investigate factors 
influencing the crystallization process in single and multiphase amorphous 
systems, as well as complexities in monitoring the progression of 
crystallization.  
The crystallization of several one- and two-phase amorphous systems were 
investigated, with the influence of both excipients and atmospheric gas on the 
crystallization process being investigated. Raman spectroscopy and X-ray 
diffractometry were used to monitor crystallization in the study, and their 
sensitivities and suitability to measure crystallization in the samples of interest 
were considered. Differential scanning calorimetry (DSC), Fourier transform 
infrared spectroscopy (FTIR) and optical microscopy were used to provide 
complementary information on crystallization processes. 
In the present thesis it was found that excipients and atmospheric gases 
that interact with amorphous material, even in the absence of mixing and 
specific interactions, can delay the onset of crystallization. Additionally, it was 
found that Raman spectroscopy is not necessarily suitable for crystallinity 
 
v 
determination, when the opacity of the sample changes, as can happen at 
temperatures above Tg. 
Overall, this thesis demonstrates that several factors, beyond those usually 
considered in traditional single-phase solid dispersions, can influence 
crystallization, and that these, together with the effect of measurement 
technique artefacts, should be carefully considered when developing 
amorphous formulations.  
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A highly organized poem 
 
In our universe, 
chaos always increases. 
One always resists; 
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When a patient takes a medicine orally for systemic delivery, the active 
pharmaceutical ingredient (API) must be dissolved to have a therapeutic 
effect. Adequate solubility of the API guarantees fast enough dissolution and a 
sufficient dissolved drug concentration in the gastrointestinal tract (GI tract). 
Even the most potent drug molecule is rendered useless, if it does not get to 
the target site, which usually would require the API to be dissolved first. 
An increasing amount of new drug molecule candidates are large in size 
and include functional groups which render them poorly water-soluble 
(Cooper, 2010; Lipinski, 2002). This is a remarkable global challenge. 
However, there are approaches to make the API more soluble. In addition to 
formulation-based solutions, the API can be made to dissolve faster, for 
example through salt or prodrug formation, reducing particle size or rendering 
the material in an amorphous form (Hancock and Zografi, 1997; Laitinen et 
al., 2013; Mu et al., 2013; Serajuddin, 1999; Vasconcelos et al., 2007; Yu, 
2001). Amorphous material is disordered, with a greater free energy and 
molecular movement than in crystalline forms (Laitinen et al., 2013). 
Amorphous forms are thus significantly more water-soluble than crystalline 
forms. On the other hand, they are physically unstable and tend to crystallize 
(Bhugra and Pikal, 2008). 
Pharmaceuticals need to be manufactured in a way that ensures the quality 
criteria to be met through the shelf life of the product. If chemical or physical 
stability fails, the drug product might lose its therapeutic effect or have a 
different effect than anticipated. Consequently, crystallization of amorphous 
materials needs to be better understood and controlled to enable amorphous 
drugs to be used more commonly and ensure safe and effective medical 
treatments. 
The overall aim of this thesis was to obtain new information on factors 
influencing the measurement and process of crystallization of amorphous 
materials. 
Review of the literature 
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Typically, solid materials composed of small molecules are in a crystalline 
form, i.e. they have long range molecular order. Many materials have multiple 
polymorphic forms. Indomethacin, for example, has at least seven 
polymorphic forms (Surwase et al., 2013), whereas xylitol has only been 
documented to have one stable form and one metastable form (Wolfrom and 
Kohn 1942; Carson et al., 1943). If no energy is added to the system, 
crystallization of an amorphous material is an irreversible process. 
Amorphous solids have the highest free energy of solid forms while 
different polymorphic forms have lower but varying levels of free energy, 
depending on their crystalline structure (Fig. 1). Solid materials tend to 
convert towards their lowest energy forms, which leads to crystallization of 
amorphous materials and polymorphic conversions between different 
polymorphs. This difference in potential energy levels for polymorphs is 
caused by the differences in molecular packing (Cui, 2007). Amorphous 
materials and different polymorphic forms have a significant role in 
pharmaceutics because of their different solubilities, as well as other 
differences e.g. in mechanical properties, packing properties, thermodynamic 
properties, kinetic properties and surface properties (Grant, 1999). 
 
 
Figure 1. A schematic representation of different forms of a substance with the same 
chemical composition. A) crystalline stable form I, b) crystalline metastable form II and 
c) unstable amorphous form. The letter e represents a single molecule. Crystal defects in 
crystalline materials have been illustrated using grey color. 
 
When crystalline material is liquefied, for example by heating above its 
melting point (Tm), molecules have higher mobility compared to in the solid 
crystalline state, where they are restricted within a certain ordered structure 
by directional intermolecular forces (Goldstein, 1968). When the liquid is 
cooled fast enough, molecules do not have enough time to rearrange and form 
long range order (crystallize) (Cui, 2007). Instead, a disordered amorphous 
solid is formed, in which there is no long-range molecular order (Cui, 2007). 
Depending on the amorphized compound, preparation method and storage 
condition, the amorphous system can remain unchanged from only seconds to 
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years (Cui, 2007). Since many pharmaceutical amorphous APIs tend to 
crystallize in a time scale that is too short for them to be used in a pure 
amorphous API form, the tendency to crystallize needs to be altered. 
Stabilization of amorphous materials is discussed in section 2.5. 
An important characteristic of any amorphous material is its glass 
transition temperature (Tg). At temperatures lower than Tg, the amorphous 
material is in the glassy state, and at temperatures higher than the Tg, it is in 
the rubbery state. A key difference between those states is that in the glassy 
state, the crystallization is less likely and slower below Tg, compared to above 
the Tg (Craig et al., 1999). This is linked to the material having a higher 
viscosity and molecular mobility at lower temperatures. 
There are multiple ways to generate amorphous materials. Methods 
commonly used on the industrial scale are freeze-drying (Lai and Topp, 1999; 
Wang 2000), spray-drying (Beyerinck et al., 2003a, 2003b), spray-freezing 
(Yu et al., 2006) and melt extrusion (Sprockel et al., 1997). Some other 
methods for preparing amorphous materials are cooling or quench cooling of 
melt, milling and grinding (Patterson et al., 2005), dehydration of hydrated 
crystals (Li et al., 2000), high pressure compaction (Smith and Gauzer, 2003) 
and electric field application (Weinhold et al., 1984). Other methods involving 
liquid (including a solution) as a starting material are antisolvent addition 
(Guillory, 1999), pH change (Guillory, 1999), vacuum systems (Szoke et al., 
2005; Abdul-Fattah et al., 2008), rapid expansion of supercritical solution 
(RESS) (Ye and Wai, 2003) and controlled expansion of supercritical solutions 
(CESS) (Pessi et al., 2016). Further methods with solid or liquid as a starting 
material are electrospinning (Igantious and Sun, 2005) and ultrasound 
(Suslick and Price, 1999; Ruecroft et al., 2005). All of them have their benefits 
and drawbacks. 
In the laboratory (on a small scale), amorphous pharmaceutical solids can 
often be made by cooling melted material either fast or slowly. Traditionally, 
it has been thought that amorphous materials need to be cooled rapidly to 
restrict molecular rearrangement during cooling and thus obtain the non-
ordered rubbery or glassy amorphous form. However, in some cases 
amorphous pharmaceutical solid might be more stable after slow cooling than 
fast cooling (Martínez et al., 2014; Willart et al., 2017). The reason for that can 
be, for example, cracks formed during fast cooling, which can lead to 
nucleation and subsequent crystallization (Martínez et al., 2014; Willart et al., 
2017). 
Review of the literature 
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An increasing proportion of new pharmaceutical drug candidates are poorly 
water-soluble. Amorphous materials may have solubilities 10 – 1600 times 
higher than those of their stable crystalline counterparts (Hancock and Parks, 
2000), which makes amorphization an attractive option. 
Low water-solubility is not only a challenge in a therapeutic sense, but also 
a great financial problem. Fewer new drug candidates are identified annually 
and an increasing proportion of the new candidates are usable in their most 
stable polymorphic form. Increasing knowledge about the amorphous form 
and crystallization is, consequently, highly valuable also from the financial 
perspective. 
In addition of different solubility of the amorphous form compared to 
polymorphs, amorphous form can have different mechanical properties, 
processability and chemical stability. 
To ensure sufficient physical stability of amorphous material for 
pharmaceutical use, the influence of aspects intrinsic to the amorphous 
material itself, as well as environmental conditions, on crystallization must be 
understood. In this section, these aspects are presented. 
Crystallization is two-step process, where first stable nuclei form and 
subsequently nuclei grow rapidly. There are many factors influencing 
crystallization initiation, such as molecular mobility and hydrogen bonding 
(Liu et al., 2006; Yu, 2001). If there are many hydrogen donors and acceptors 
in the molecule, they can form many relatively strong hydrogen bonds between 
the molecules in the amorphous form (Bhende and Jadhav, 2012). This can 
lead to a situation where the material is less likely to form ordered groups of 
molecules (Bhende and Jadhav, 2012). Consequently, stable nuclei are not 
easily formed. Additionally, molecules need to overcome possible steric 
hindrance, which prevents molecules from having contacts between suitable 
functional groups and consequently form stable nuclei (Ovshinsky, 1985). 
There are two types of crystallization – homogeneous and heterogeneous. 
Çelikbilek et al. (2012) have summarized the difference: “The nucleation either 
occurs without the involvement of a foreign substance in the interior of the 
parent phase, which is called “homogeneous or primary nucleation” or with 
the contact of the parent phase with a foreign substance that acts as a preferred 
nucleation site which is called “heterogeneous or secondary nucleation”. A 
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factor causing heterogeneous nucleation can be for example container walls 
(Çelikbilek et al., 2012), impurities (Viel et al., 2017) and excipients (Bhatt et 
al., 2015; Martínez et al., 2014; Hellrup and Mahlin, 2011). Also cracks can 
cause heterogeneous nucleation by greatly increasing the surface area in 
contact with the gas phase (Patterson et al., 2005; Dudognon et al., 2008). If 
heterogeneous nucleation is possible, it is usually favored, since it requires less 
free energy than homogeneous nucleation (Turnbull, 1950). 
Small inflexible molecules tend to crystallize easier than large flexible 
molecules. In addition to more pronounced steric hindrance effects, bigger 
molecules have more degrees of freedom with respect to their molecular 
conformation, as well as possible hydrogen bonding interactions, which can 
complicate formation of crystal structure (Almarsson and Gardner, 2003; 
Almarsson and Zaworotko, 2004). 
While the most suitable amorphized materials for pharmaceutical 
development are those that do not crystallize easily, rapidly crystallizing 
materials are useful for general research into crystallization behavior, 
including external factors that can affect crystallization. Rapidly crystallizing 
systems can provide new information on crystallization without taking years 
– or decades. Thus, it is beneficial to investigate systems that crystallize fast 
and later on investigate systems that crystallize slower. 
When amorphous material is manufactured by grinding, it is likely to contain 
some seed crystals of some polymorph of the original crystalline material 
(Sandhu et al., 2014). These seed crystals may act as nuclei to start crystal 
growth. Residual crystallinity or the presence of any crystalline material in the 
amorphous material, regardless of the manufacturing process used, can be a 
problem, especially when the nucleation step during crystallization is 
circumvented. 
When amorphous material is in contact with a foreign surface, the presence of 
the foreign surface can lead to crystallization (Hellrup and Mahlin, 2011; Bhatt 
et al., 2015). Such surfaces can be interfaces between amorphous material and 
gaseous phase (Byrn et al., 2001; Chen et al. 2002), container (Martínez et al., 
2014) or other material in two-phase or multiple-phase systems (Yu et al., 
1998). Two- or multiple-phase systems include controlled and uncontrolled 
impurities. However, in some cases additives can also lead to stabilization of 
Review of the literature 
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the amorphous system as discussed in section 2.5. Having cracks in the system 
makes the solid-gas interface much bigger, which leads to crystallization being 
more likely (Martínez et al., 2014; Willart et al., 2017). 
When two materials with different Tgs are mixed on a molecular level, they can 
attain one Tg (Hancock and Zografi 1994). Since water has a Tg of -135°C 
(Haque and Roos, 2003), it can lower the Tg of amorphous material 
significantly, especially, since amorphous materials tend to adsorb more water 
than crystalline materials. As an example, it has been reported that when water 
content of amorphous xylitol is 0%, its Tg is -24°C (Talja and Roos, 2001). The 
Tg is -53°C when the water content is 10% and -93°C when the water content 
is 40%. When the Tg decreases below storage temperature, amorphous 
materials become rubbery (Yu, 2016). The lower viscosity is associated with 
increased molecular mobility. Consequently, diffusion of molecules in the bulk 
increases, leading to an increased crystallization rate. 
There has been a lack of systematic research into the effect of atmospheric 
gases other than water on the crystallization of amorphous materials. The lack 
of research is somewhat surprising, since the interactions between molecules 
in solid and gaseous phases are known to take place and water is known to 
have a significant impact on the stability of amorphous materials. As stated 
earlier in the thesis (2.4.1), hydrogen bonds play a very important role in 
crystallization. If the gas can interact with the functional groups that would 
otherwise form hydrogen bonds with other molecules in the amorphous 
material, gas may have an effect on crystallization.  
Amorphous materials are known to interact more freely with atmospheric 
water than their crystalline counterparts. Also other gases have been reported 
to act similarly. According to Byrn et al. (2001) amorphous DL-Ala-DL-Met-
dipeptide oxidized to a significantly higher extent than its crystalline 
counterpart. This indicates that amorphous material interacted more with 
oxygen than its crystalline counterpart, which is likely due to the amorphous 
materials having higher free volume, greater molecular mobility and more 
possibility for forming new bonds. Di Martino et al. (2000) reported that when 
subjecting amorphous indomethacin or crystalline α-indomethacin to gaseous 
ammonia, indomethacin chemically reacted with the gas. However, crystalline 
γ-indomethacin did not react with the gas. The study showed that interaction 
with the gaseous phase requires an exposed reactive functional group. 
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Some molecular movement is needed for nuclei to form. Nucleation is fastest 
near the Tg (Craig et al., 1999). However, between Tg and Tm the nucleation 
rate decreases, when the movement of molecules increases. However, since the 
crystal growth is faster at higher temperatures, the overall-crystallization can 
increase, when the temperature increases. 
The glassy state (temperature below Tg) is more physically stable than the 
supercooled state (temperature above Tg), but in both cases crystallization may 
occur, although it is more likely in temperatures above Tg (Ediger et al., 1996). 
It has been said that to guarantee stability, amorphous materials should be 
stored at a temperature that is at least 50°C lower than Tg. However, for some 
materials this temperature difference is not sufficient, since it has been 
reported that crystallization might occur even 175°C below Tg (Okamoto and 
Oguni, 1996). Additionally, one must remember that humidity lowers the Tg, 
which can also have a major impact on finding suitable storage conditions for 
amorphous materials. 
 
When amorphous material is processed, it may be exposed to conditions that 
may cause it to crystallize. Roughly, process-induced crystallization can be 
divided into water-induced crystallization, heat-induced and pressure induced 
crystallization. Some processes can be in multiple categories. 
After preparation of amorphous material, milling can be needed to make 
formulation of the material possible. Milling can lead to a rise in temperature 
(Morales et al., 2012), which makes crystallization of the material more likely 
(Craig et al., 1999; Ediger et al., 1996). Additionally, shear forces introduce a 
large amount of energy to the system (Merisko-Liversidge et al., 2003), which 
can have an effect on crystallization. Other processes used during the 
manufacturing of the drug product that expose the material to heat are 
granulation (Sandhu et al., 2014) and tableting (DeCrosta et al., 2001). In 
tableting, the material is exposed to high pressure, which can lead to 
crystallization of amorphous materials (Lakio et al., 2015). Granulation can 
also expose the material to a solvent, often water (Sandhu et al., 2014). In the 
coating process, amorphous material can be exposed to water as well as heat 
(Sandhu et al., 2014; Sauer et al., 2013). 
Considering the outcome of medical treatment, it is not sufficient to have an 
amorphous system that remains stable through the shelf-life of the product. 
The amorphous form needs to withstand the conditions it is subjected to upon 
administration. It is known that amorphous systems may recrystallize when in 
Review of the literature 
8 
contact with aqueous media, whereby the stability advantage is lost and the 
active ingredient is rendered ineffective (Alonzo et al., 2010). In the GI tract, 
the drug environment changes drastically. It faces highly acidic and less acidic 
aqueous conditions. The rough and changing conditions may lead to 
amorphous drug crystallizing, which may lead it to losing the enhanced 
solubility properties, which can restrict dissolution rate to be the same or even 
lower than it would have with stable crystalline form. 
Protecting amorphous material from elevated humidity and temperature is 
not always enough to guarantee stability of the amorphous form long enough 
time for therapeutic use. Consequently, stabilizing agents often need to be 
added to ensure the amorphous drug remains stable. These agents can be for 
example polymers, sugars, amino acids or porous materials. In this section, 
sugars and porous materials are described more in depth. 
To get two or more materials to form a stable amorphous system, they need 
to have sufficiently strong molecular interactions to prevent similar molecules 
from forming bonds and starting to form nuclei (Bughra and Pikal, 2008). 
Optimally, the materials are miscible and can be mixed on a molecular level to 
form one homogeneous phase (Brough and Williams, 2013). However, also 
two-phase systems can prevent crystallization (Semjonov et al., 2017). 
In the stabilization of small molecules in an amorphous form, commonly 
used group of excipients is polymers (Asmus et al., 2012; Baghel et al., 2016; 
Vaka et al., 2014). Due to their long chains, they can form a wide network, 
which prevents amorphous small molecules moving freely, which prevents 
crystallization (Baghel et al., 2016; Vaka et al., 2014). 
Usage of non-ordered mesoporous silica and other porous materials is 
based on their ability to absorb small drug molecules into the pores and 
interact with drug molecules, preventing them from crystallizing (Kinnari et 
al., 2011; Limnell et al., 2011). In earlier studies, silica (Syloid 244 FP) has been 
loaded with drug using immersion (Kinnari et al., 2011; Limnell et al., 2011), 
rota-evaporation (Limnell et al., 2011) and fluid bed processing (Limnell et al., 
2011). With such loading, the molecules cannot get in contact with each other 
in large enough quantities to be able to form stable nuclei and/or support 
crystal growth. 
Sugars are typically used in the stabilization of amorphous protein 
formulations (Davidson and Sun, 2001; Lipiäinen et al., 2016, 2018). They can 
immobilize the protein molecules, and inhibit unfolding as well as aggregation 
(Izutsu et al., 1993; Mensink et al., 2013). Small molecule excipients have been 
found more efficient in protein stabilization than larger molecules, since small 
molecules have a better ability to form direct bonds with proteins compared to 
larger molecules (Mensink et al., 2017; Tonnis et al., 2015). 
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In addition to protein stabilization, small molecules, such as amino acids 
and sugars, can be used to stabilize other small molecules. In some cases, two 
small molecules can form a co-amorphous system, which can prevent 
crystallization effectively (Chavan et al., 2016; Gao et al., 2013; Löbmann et 
al., 2013a, 2013b, 2013c). In other cases, they can form two-phase systems, in 
which crystallization is prevented or postponed (Brough and Williams, 2013; 
Semjonov et al., 2017).  
There are many techniques that can be used when characterizing 
amorphous pharmaceuticals and different polymorphs (Chieng et al., 2011).  
Spectroscopic measurements that probe materials on the molecular level 
include: 
• Raman spectroscopy 
• Mid-IR, including Fourier transform infrared (FTIR) spectroscopy 
• Near infrared (NIR) 
• Solid-state nuclear magnetic resonance (ss-NMR).  
Measurement techniques that probe the particulate level include: 
• Terahertz pulsed spectroscopy (TPS), 
• X-ray methods including single crystal X-ray diffraction (SCXRD), 
small-angle X-ray scattering (SAXS) and wide-angle X-ray 
scattering (WAXS), which in pharmaceutical studies, is often 
referred as powder X-ray diffraction (PXRD or XRPD) 
• Thermoanalytical and gravimetric analyses, including differential 
scanning calorimetry (DSC), modulated temperature differential 
scanning calorimetry (MTDSC), thermogravimetric analysis (TGA), 
dynamic vapor sorption (DVS), isothermal microcalorimetry (IMC) 
and solution calorimetry (SC) 
• Microscopy, including polarized light microscopy (PLM), with or 
without a hot/cryo/freeze-drying stage, and scanning electron 
microscopy (SEM). 
 
From these, WAXS (I-III), DSC (I-III) and PLM (I-II) are presented in 
more detail in this section. Additionally, data analysis is discussed in this 
section. 
X-ray diffraction crystallography is the primary method used when studying 
crystallinity, crystallite size or polymorphism of pharmaceutical compounds. 
It is based on scattering of X-rays caused by the electron clouds of individual 
atoms in the sample. Based on data collected from variations of the intensity 
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of scattered x-rays, information on atomic packing, interatomic forces and 
angles can be obtained (Dong and Boyd 2011). Unknown materials cannot be 
identified using x-ray diffraction, since the method does not provide 
information on chemical composition (Chieng et al., 2011). However, 
polymorphic forms of known substances can be identified. When studying 
amorphous systems, x-ray scattering is an indirect method, which does not 
provide direct structure information on disorder, but rather on the lack of 
order. 
 
Differential scanning calorimetry (DSC) is a method that provides quantitative 
information about endothermic reactions (such as melting) and exothermic 
reactions (such as crystallization) as a function of time and temperature (Clas 
et al., 1999). Also heat capacity changes (such as glass transition) can be 
investigated. Detecting the glass transition enables detection of 
amorphousness, and detecting the melting peak can enable determination of 
the polymorphic form of the investigated material (Clas et al., 1999). The effect 
of water on the Tg may be observed (Talja and Roos, 2001). Impurities may be 
detected (van Dooren and B.W. Müller, 1984; Giron and Goldbronn, 1993). All 
of these can help to further understand the results of other measurements. 
Infrared (IR) spectroscopy is a method that is based on energy absorption 
associated with vibrations of atoms in molecules (Berthomieu and 
Hienerwadel, 2009; Blum and John, 2012). The introduction of Fourier 
transform spectrometers has dramatically improved the quality of data due to 
the much better signal-to-noise ratio (Blum and John, 2012). For the molecule 
to be detectable with IR a change in dipole moment is needed, which typically 
happens with asymmetric vibrations of polar functional groups (Berthomieu 
and Hienerwadel, 2009). It can be used to differentiate polymorphs and 
amorphous samples and to quantify crystallinity (Akao et al., 2001; Amado et 
al., 2017). Additionally, it can be determined whether or not a mixture has 
molecular interactions between the components, in particular hydrogen 
bonding (Crupi et al., 2007; Löbmann et al., 2013c). 
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Raman spectroscopy is based on inelastic scattering of monochromatic (laser) 
light caused by molecular vibrations associated with a change in polarizability 
(as opposed to a change in dipole moment for FTIR) (Colthup et al., 1990; 
Larkin, 2011). As a result, a small portion of the incident light is scattered at 
slightly longer wavelengths (Stokes scattering) or even more rarely at shorter 
wavelengths (anti-Stokes-scattering). Stokes and anti-Stokes scattering are 
collectively known as Raman scattering. Raman spectroscopy is best in 
detecting symmetric vibrations of non-polar groups, and is relatively 
insensitive to water (Larkin, 2011). When using Raman spectroscopy, 
fluorescence can be a big problem. Typically, it can be seen as an elevated and 
curved baseline in the measured Raman spectra of the sample 
(Pelletier,2003). However, when measuring highly fluorescent samples, such 
as colored samples, the Raman response can be completely masked by the 
fluorescence (Pelletier,2003; McCreery, 2000). This interference can be at 
least partially avoided by, for example, using a longer laser wavelength that is 
less likely to induce fluorescence (e.g. 785 nm instead of 532 nm). When IR 
and Raman sample preparation are compared, Raman measurements are 
generally simpler. With Raman spectroscopy the sample does not need to be 
in contact with the probe and/or diluted. 
 
In many cases, when multiple spectra are involved and differences between 
the spectra are of interest, the spectral data need to be pretreated and 
processed using multivariate analysis. There can be variations in intensity and 
changes in baseline, which could be caused by differences in particle size, 
density, sample packing and fluorescence (Pellow-Jarman et al., 1996; 
Savolainen et al., 2006). Additionally, in the vibrational (e.g. Raman) spectra 
interpretation can be complicated by overlapping peaks and subtle changes 
that can be impossible to detect visibly (Heinz et al., 2009; Aaltonen et al., 
2008). Combined these do not enable e.g. comparison of peak intensities or 
areas. A combination of suitable pretreatment and multivariate methods is 
valuable for both qualitative and quantitative spectral interpretation and can 
make results more reliable. 
The effect of baseline differences can be overcome using baseline correction 
or derivatives. To remove overall spectral intensity differences, for example, 
standard normal variate (SNV) or multiplicative scatter correction (MSC) can 
be used. Usage of carefully selected spectral pre-treatments can make 
multivariate analysis more reliable (Savolainen et al., 2006). They are 
compared in detail in section 5.1.2. 
The most common multivariate analysis methods for spectral data in 
pharmaceutical sciences have been divided into two categories: classical least 
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squares analysis (CLS) and inverse least squares analysis (ILS) approaches 
(Strachan et al., 2007). CLS is recommended to be used when all components 
of the sample are known. It can be divided to direct and indirect CLS. ILS 
approaches are recommended to be used, when not all components are known. 
Common ILS methods are multiple linear regression (MLR), principal 
components regression (PCR, principal component analysis (PCA) combined 
with linear regression) and partial least squares (PLS).  
Optical microscopy can be used to visually examine samples and confirm 
findings from other techniques. It is an additional method that can be used to 
visually examine the difference in crystallite size and polymorphism based on 
the crystal habit (Greco and Bogner, 2010). When polarized light is used, 
amorphous and crystalline areas of the sample can be differentiated, since, 
between cross polarizers, birefringent crystals rotate the plan of the polarized 
light and appear brightly colored, while isotropic amorphous particles do not 
and appear dull/black (Kestur and Taylor, 2013; Wu et al., 2007). 
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The overall aims of this thesis were to obtain new insights into the 
crystallization of non-traditional two-phase amorphous systems and the effect 
of the gaseous phase on the crystallization of amorphous material. 
Furthermore, the thesis set out to bring new insights into the characterization 
of crystallization of these systems. 
 
The specific objectives were: 
• to investigate effect of analytical technique and data processing 
method on quantification of crystallization of rapidly 
recrystallizing systems at temperatures above Tg (I) 
• to investigate how atmospheric gases affect the onset of 
crystallization of amorphous API (II) 
• to study the effect of excipients on crystallization of two-phase 
amorphous solid dispersions (I, III).  
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Several model substances were used in the crystallization studies I-III. The 
starting materials were crystalline xylitol (University Pharmacy, Finland) (I) 
and crystalline paracetamol form I (Orion Pharma, Finland) (II-III). To alter 
crystallization of these substances, non-ordered mesoporous silica (Syloid 244 
FP, Grace GmbH & Co., KG, Germany) (I), D-(+)-trehalose dihydrate (Sigma, 
USA) (III) and D-melibiose monohydrate (Senn Chemicals, Switzerland) (III) 
were used. Additionally, ibuprofen (Boots Pharmaceuticals, United Kindom) 
(I) and γ-indomethacin (Orion Pharma, Finland) were used in the Raman 
spectroscopy penetration depth studies (I). 
Xylitol and non-ordered mesoporous silica were kept over silica gel in a 
desiccator for at least two weeks prior to the experiments to minimize water 
content (I). In article II, the paracetamol samples were kept in a glove box with 
set atmospheres of humid air, dry air, dry carbon dioxide (CO2) or dry nitrogen 
(N2) at least 10 minutes in equilibrium humidity before the melting process. 
Xylitol (I) is a small sugar alcohol, which is often used as a sweetener. It 
has a molar mass of 152.1 g/mol. Amorphous xylitol has a very low Tg of -24°C 
(Talja and Roos, 2001) and only one stable polymorphic form and one 
metastable form are known (Carson et al., 1943; Diogo et al., 2007). These 
factors make xylitol a good model compound for investigating rapid 
recrystallization.  
Non-ordered mesoporous silica (I) is a material composed of particles with 
nanosized pores, which can be loaded with drug molecules. In the case of 
Syloid 244 FP, the particle size is 2.5 – 3.7 μm and the pore volume is 1.6 ml/g 
(Grace GmbH & Co., 2015). Depending on the pore size, surface area and 
surface chemistry, the material can be suitable for stabilizing different drugs 
in the amorphous form (Xu et al., 2013). In this study, non-ordered 
mesoporous silica (also referred to in the thesis as silica) is used to alter the 
crystallization rate of amorphous xylitol. In this study, mixing was performed 
using the melting. The ratio of silica to API in this study was less than in most 
previous studies, where aim has been to the fill pores and have no free API. In 
this case, a lower proportion of silica was used, to allow higher drug loadings 
and simultaneously allow the effects of simple mixing on crystallization and 
its measurement to be investigated. 
Paracetamol (II-III) is a non-steroidal analgesic drug. It was selected 
based on it being representative of typical organic drugs having an aromatic 
polyfunctional structure. It has a molecular weight of 151.2 g/mol. 
Paracetamol has three polymorphs, of which form I is the stable form (Perrin 
et al., 2009). It has a Tg in the region of 22 – 26°C (Qi et al., 2008). 
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Trehalose (III) and melibiose (III) are disaccharides with a molecular 
mass of 342.3 g/mol. There is a wide range of Tgs reported for trehalose, with 
values varying between 100 and 120°C, but most listed are in the range of 115 –
120°C (Hancock and Dalton, 1999; Hancock and Zografi, 1997; Heljo et al., 
2012; Kadoya et al., 2010; Quo et al., 1999; Roos, 1993; Surana et al., 2004; 
Sussich et al., 1998). Melibiose has been reported to have Tgs of 85°C (Roos, 
1993), but also 100°C (Heljo et al., 2012). Trehalose is widely used in protein 
stabilization, with melibiose having been studied to a lesser degree. Heljo et 
al. (2012) and Lipiäinen et al. (2016, 2018) have compared these disaccharides 
in protein stabilization. However, these disaccharides have not been compared 
in stabilizing small molecules, even though trehalose has been successfully 
used in small molecule stabilization earlier (Mazzobre et al., 2003; Horvat et 
al., 2005; Luthra et al., 2008). 
In all cases, amorphous samples were prepared using melting and cooling (I-
III). This sample preparation section is arranged according to measurement 
technique, with more specific sample preparation details mentioned where 
appropriate within these subsections.   
In article I, the whole sample preparation process from melting to closing the 
sample holder was done in a glove box with a dry nitrogen atmosphere. A 
sample size of 1.35 g was used, since the amount could fill the sample holder. 
The sample holder enabled in situ analysis with both X-ray and Raman 
measurements and kept the atmosphere similar between measurements. 
Amorphous xylitol was prepared by melting crystalline xylitol powder on a hot 
plate at 180°C, which is well above the melting point of xylitol (92 – 96°C). 
This ensured proper mixing with silica and was well below the boiling point of 
xylitol (215 – 217°C). Non-ordered mesoporous silica 10% (m/m) was mixed 
into the molten xylitol. The mixture of molten xylitol and silica was quench-
cooled and ground roughly in liquid nitrogen. When most of the liquid 
nitrogen had evaporated, the sample was poured into the sample holder with 
left over liquid nitrogen. When the liquid nitrogen had totally evaporated, the 
sample was sealed in the sample holder between two plastic films. The plastic 
films were 6 μm thick Mylar films made from the resin polyethylene 
terephthalate (PET). This was done to ensure a repeatable dry nitrogen 
atmosphere inside the sample holder. The final samples had a diameter of 15 
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mm and a thickness of 2 mm. WAXS and Raman measurements were initiated 
4 min after complete liquid nitrogen evaporation. 
For crystallinity quantification based on Raman spectroscopic data, 
reference samples of xylitol with crystalline contents of 0% (n=5), 10% (n=3), 
25% (n=3), 40% (n=3), 50% (n=5), 60% (n=3), 75% (n=3), 90% (n=3) and 
100% (n=5) were prepared. The amorphous fraction of the sample was 
prepared as described above. A known amount of crystalline xylitol was added 
to the xylitol-liquid nitrogen dispersion and gently ground to create the 
mixture. Since silica gave a negligible Raman response, a second reference set 
with silica was not prepared. 
With the WAXS measurements, the quantitative model was based on 
diffractograms of the average of the first three minutes of the amorphous 
xylitol measurement, crystalline xylitol and non-ordered mesoporous silica. 
The xylitol crystallinity values were then calculated from the areas under the 
sample intensity curve of xylitol and the amorphous contribution. The xylitol 
crystallinity values were normalized with the average crystallinity value of the 
crystalline xylitol measurement.  
In article II, the whole sample preparation process from melting to closing 
the sample holder was done in a glove box with set atmospheres of dry air with 
a relative humidity of 4.4 – 4.7%, nitrogen (N2) with a relative humidity of 
0.0 – 0.1%, carbon dioxide (CO2) with a relative humidity of 1.2 – 1.5% or 
humid air with a relative humidity of 21.1 – 22.2%. The gases were conducted 
into the glove box using a pressure of 1.6 bar. In this study, 10.00 ± 0.08 mg 
of crystalline paracetamol was placed on the sample holder and melted on a 
hot plate for 3.5 – 4 min. The temperature was set to 210°C, but, due to heat 
loss, the sample reached a temperature of approximately 190°C. The sample 
was cooled down to the temperature prevalent in the glove box (15.55 ± 
0.45°C) using a metal block with a temperature of 13.15 ± 0.25°C. The sample 
holder was closed containing the selected atmosphere, whereby the sample 
was ready for Raman measurements. The first measurement point was 10 min 
after cooling in all experiments. Reference samples of amorphous 
paracetamol, and crystalline paracetamol forms I and II were made according 
to Kauffman et al. (2008). These reference samples were made in triplicate. 
To determine if PCA could be directly used in crystallinity determination, 
reference samples with varying crystallinities consisting of amorphous and 
form II of paracetamol were prepared. 
In article III, 1.00 g of sample containing 25%(m/m) of paracetamol and 
75%(m/m) of sugar (melibiose or trehalose) was spread in the aluminum pan 
to increase the contact area and reduce melting time as much as possible. The 
sample was mixed during melting using a spatula to get sample as 
homogeneously mixed as possible. Melting temperatures were 195°C for 
paracetamol, melibiose and paracetamol-melibiose samples and 215°C for 
trehalose and paracetamol-trehalose samples to ensure complete melting of 
the sample. Heating was continued 20 sec after appearing completely molten 
to ensure that the sample was fully melted and thus amorphous. Longer 
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melting times exposed the sample to chemical degradation, which could be 
seen as color changes. Cooling was performed in a glove box with nitrogen 
atmosphere by pouring liquid nitrogen into the pan. In 4 s, the sample had 
reached the temperature of liquid nitrogen. Residual liquid nitrogen was 
poured out of the pan after 1 min. The sample was transferred into a mortar, 
ground, transferred to the sample holder and sealed in the sample holder. The 
sample holder had a set volume and plastic films (Mylar) on top and below the 
sample. The final sample sizes were 151 ± 8 mg. Preparation was followed by 
WAXS measurements. 
In all articles (I-III), samples showing any sign of possible degradation (as 
evidenced by a color change) were discarded from the crystallization behavior 
analyses. In crystallization studies I-II, the samples were not moved during 
the continuous measurements. In article III, the sample was stored at 38 ± 
0.5°C and 75 ± 1% and 3 ± 1% relative humidities between measurements. 
All DSC samples were prepared in 40 μl aluminum pans and the pans were 
covered with pinhole lids to allow humidity evaporation. Amorphous samples 
in the sample holder (II) were made similarly as the Raman spectroscopy 
samples, but the sample was detached from the microscope slide and 
transferred to the DSC pan. Other samples (I-III) were taken from bulk or 
from ground material, and measured as such. Samples were weighed using an 
analytical balance. 
Samples for FTIR analysis were produced the same way as for WAXS analysis. 
However, amorphous paracetamol reference samples were not ground, since 
it crystallized so rapidly that grinding would have caused it to crystallize before 
measurement. 
Separate amorphous xylitol and amorphous xylitol-silica dispersions (I) were 
produced in a similar manner to that described above in section 4.2.1.1. 
Samples were set as thin layers on microscope slides. Additional samples were 
made by placing some of the final products on microscope slides, molten and 
quench cooled by dipping the sample to liquid nitrogen.  
In article II, paracetamol samples were prepared in a dry nitrogen 
atmosphere in a similar manner as for the Raman spectroscopy samples 
described above in section 4.2.1.1. 
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In this section, the technical aspects of all analytical methods used in this 
thesis are presented. WAXS and Raman spectroscopy were used to monitor 
crystallization. WAXS measurements were done in transmission mode, so that 
the whole sample was equally represented, whereas with Raman spectroscopy, 
the measurements were based on back scattering, which meant that the upper 
region in the sample (closer to the sampling probe) was over-represented. DSC 
was used to measure Tg, recrystallization and Tm, which could give more 
information on possible differences of the Tg, which could explain possible 
shifts in onsets of crystallization and changes in recrystallization rates. 
Additionally, DSC was used in determining polymorphic forms of the end 
products. Optical microscopy was used to visually observe how crystallization 
progressed and evaluate the crystallite sizes present in the end products. FTIR 
spectroscopy was used to detect possible interactions between components of 
the solid dispersions. 
In article I, WAXS measurements were performed using a Rigaku rotating-
anode based X-ray set-up (Kontro et al., 2014) with a Pilatus 1M detector. The 
beam size was 1 mm2. Measurement times were 5 or 15 s and measurements 
were conducted continuously. These diffractograms were averaged over 60 s 
and corrected as described in Dixon et al. (2015). Overall measurement times 
were 15 min for crystalline xylitol reference, 90 min for amorphous xylitol and 
150 min for the xylitol-silica dispersion. Amorphous xylitol reference was 
combined from the diffractograms of first 3 min of the amorphous xylitol 
measurement. The measurements were performed at ambient conditions: 
19.2 – 31.3% relative humidity and 28.7 – 29.3°C temperature (detected 
outside the sample holder). 
In articles II-III, WAXS measurements were performed using an 
Empyrean X-Ray diffractometer (Panalytical, Almelo, Netherlands). A fixed 
divergence slit of 0.19 mm, general voltage of 45 kV and tube current of 40 mA 
were used. 
In article II, the step size was 0.01313°, the measured angular range was 
5 – 50° and the overall measurement time was 24.45 min. Measurements were 
conducted in reflection mode. The resulting polymorphic forms of the selected 
samples were measured from samples that were exposed to atmospheric gases 
of dry air, humid air or nitrogen and the highest and lowest temperatures were 
investigated. The purpose of the WAXS measurements was to confirm that the 
samples had converted to the polymorphic form indicated in the Raman 
spectra. 
In article III, the step size was 0.01313°, the measured angular range was 
5 – 25° and the overall measurement time was 6.2 min. A narrower angular 
range was selected to make measurement faster and consequently minimize 
sample exposure to lower temperatures of 25 – 27°C. A 10 mm x 10 mm area 
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was measured using Parabolic Mirror transmission. The sample holder was 
kept closed during the measurement and open while stored at the temperature 
of 38 ± 0.5°C and relative humidity of 75 ± 1%. Those conditions are within the 
limits of elevated temperature and humidity conditions set for stability 
studies. Crystallization observations of 1:3 solid dispersions of amorphized 
paracetamol-trehalose and paracetamol-melibiose were done in triplicate. 
All DSC samples were measured using differential scanning calorimetry (DSC; 
DSC823e, Mettler-Toledo Inc., Switzerland). In every measurement the 
heating rate was 10°C/min. 
In article I, bulk xylitol and non-ordered mesoporous silica, as well as 
examples of freshly prepared quench-cooled samples and examples of 
crystalline end products were analyzed. The samples were cooled to -50°C, 
heated to 0°C, re-cooled to -50°C and heated up to 140°C. 
In article II, bulk paracetamol, representative samples of freshly prepared 
amorphous materials and end products that were kept at 18.3°C or 28.3°C 
were measured. Samples were held at -20°C for 5 min and heated to 200°C. 
In article III, reference samples, amorphous samples of paracetamol, 
trehalose and melibiose and physical mixtures of paracetamol-trehalose and 
paracetamol-melibiose were measured. Additionally, each batch used in 
WAXS measurements was analyzed immediately after preparation and after 
crystallization. All samples were kept at 10°C for 5 min, heated to 100°C, 
cooled to 0°C and heated up to 250°C. 
FTIR analyses were done using a single-reflection MIRacle attenuated total 
reflectance (ATR) crystal (Pike Technologies, Wisconsin, USA) and a Vertex 
70 spectrometer (Bruker Optics, Ettlingen, Germany). Data was collected 
using OPUS 5.5 (Bruker Optics, Ettlingen, Germany) software. Each spectrum 
was the average of 256 scans and the spectral resolution was 4 cm-1. The used 
spectral range was 1400−1800 cm−1. 
All Raman spectroscopy measurements (I-II) were done using a Raman 
RXN1-PhAT-785-D spectrometer (Kaiser, USA) and a PhAt system probe head 
(Kaiser optical systems, Inc., USA). The laser source had a laser power of 400-
mW and a wavelength of 785 nm (Raman RXN1-PhAT-785-D, Kaiser optical 
systems, Inc., USA). The spectral resolution was 0.3 cm-1 and Raman shifts 
between 200 cm-1 and 1800 cm-1 were used. The beam diameter was 6 mm, 
which is relatively large. A larger beam diameter minimizes the spectrometer’s 
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sensitivity to inhomogeneities of sample and the exact positioning of the 
sample (Johansson et al., 2005; Paudel et al., 2015). Additionally, when the 
effect of laser power is spread over a larger area, the heat load becomes 
smaller. In all measurements, one result was the average of three scans. In 
article I, the measurement integration time was 2 s. In article II, the 
integration time was 0.5 s. 
In article I, two different recrystallization measurement sets were 
investigated. In the first measurement set, the relative humidity was 21 – 35% 
and the temperature was between 20.1 – 21.6°C. The recrystallization process 
was observed for 6 hours with 1-min intervals. In the second measurement set, 
recrystallization was performed at an elevated temperature of 28.5 – 29.5°C 
and relative humidity of 19 – 25%. These conditions corresponded to the 
conditions in the WAXS measurements. Measurements were performed at 5-
min intervals until the sample was fully crystalline. These crystallization 
experiments were done in triplicate. Every reference sample was done in 
triplicate, except the 0%, 50% and 100% samples, which were done as five 
separate samples. 
In article II, the Raman measurements were performed through the 
bottom of the sample. In the re-crystallization experiments, spectra were 
collected at 30-sec intervals. Measurement sets were performed at four 
temperatures: well below onset of Tg (17.2 ± 0.3°C), slightly below onset of Tg 
(21.7 ± 0.2°C), slightly above onset of Tg (23.9 ± 0.4°C) and well above onset 
of Tg (27.5 ± 0.2°C). The reference samples were measured three times each. 
 
In articles I-II, a polarizing light microscope (Nikon Optishot; Tokyo, Japan) 
was used. Measurements were performed at ambient conditions (I) or in a N2 
atmosphere and 20.5 – 21.4°C temperature (II). 
In this section, the pretreatment and data analysis performed on the WAXS 
and Raman spectroscopy results are presented. 
In article I, reference samples of bulk xylitol and non-ordered mesoporous 
silica were used to assess the contribution of xylitol and silica in solid 
dispersions using least-squares fitting. Based on the WAXS results, in the 
measured area, the sample was composed of 13% of silica. This amount was 
expected to be constant during measurements and the silica contribution to 
the diffractogram was subtracted from all the data points of xylitol-silica 
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dispersion, which led to data representing only xylitol. Crystallinity values 
were obtained from the amorphous xylitol scattering patterns and the sharp 
diffraction peaks. Crystallinity values of xylitol were calculated from the areas 
under the sample intensity curve and amorphous contribution.  
In article II, X-ray diffractometry was used to confirm the polymorphic 
form of paracetamol after crystallization monitoring with Raman 
spectroscopy. Paracetamol polymorph identification was done by visual 
inspection of the diffractograms.  
In article III, there were two crystallizing materials in each sample. 
Therefore, the method to determine crystallinity described earlier in this 
section could not be used. The crystallinities of paracetamol, melibiose and 
trehalose samples were determined using selected peak heights from the X-
ray diffractograms. Before height determination, HighScore Plus (Malvern 
Panalytical Ltd, Malvern, United Kingdom) was used to subtract the baseline 
from the input data. In the software, the sending factor was set to 30 and 
granulatory to 40. Peak positions were determined using minima of the 2nd 
derivatives and the peak heights were determined in the same software. 
A sample-mass-based correction factor was used to ensure as accurate 
crystallinity determination as possible. The selected peaks (2θ) were at 9.8° 
for crystalline melibiose, at 14.6° for crystalline trehalose and at 18.2° for 
crystalline paracetamol. Calibration samples for the quantitative model were 
done in triplicate and contained crystalline paracetamol and excipient in 
fractions of o, 25, 50, 75 and 100%. R2-values for the linear fittings (set 
intercept to 0) were 0.948 for paracetamol, 0.806 for trehalose and 0.934 for 
melibiose. The lower R2-values for the trehalose model were assumed to be 
caused by the overlapping shoulder of another peak. 
Since the Raman peaks of amorphous and crystalline xylitol are overlapping, 
PLS regression was used to analyze the Raman spectra. The Raman shift range 
(835.2 – 1145.4 cm-1) used in the PLS model was selected to ensure most of the 
strong and moderate characteristic peaks were included (de Veij et al., 2009). 
These peaks include the in-phase ν(CCO) stretching vibration at 872 cm-1 and 
the peaks in the 1000 – 1150 cm-1 range, representing the out-of-phase δ(CCO) 
stretching vibration. Additionally, the range was only mildly affected by 
fluorescence. 
Extensive investigation to reveal and the select the best combination of 
pretreatments was performed prior to PLS modelling. Pretreatments 
contained baseline correction, mean centering, Savitzky-Golay 1st and 2nd 
derivatives, standard normal variate (SNV) and multiplicative scatter 
correction (MSC). MATLAB (MatLab R2014b, MathWorks Inc., Natick, 
Massachusetts, United States) was used for all spectral pretreatments, except 
MSC, which was done using SimcaP 10.5 (Umetrics AB, Umeå, Sweden). The 
baseline correction was done with Matlab function msbackadj (windowsize 25, 
Experimental 
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stepsize 25). The selection of the best combination of pretreatments is 
presented in section 5.2. 
To identify which polymorphic form of paracetamol crystallized, three 
reference samples of amorphous paracetamol, paracetamol form I and 
paracetamol form II were prepared using the method described by Kauffman 
et al. (2008). Form III could not be prepared, because the sample holder did 
not allow a method where it could have formed. Spectra were pretreated with 
Savitzky-Golay smoothing (window size 9, 3rd degree equation) and 1st 
derivative transformation. PCA was used to analyze the spectral range of 
1586.7 – 1686.3 cm−1. The spectral range was selected because it includes two 
characteristic peaks, which reveal the polymorphic form of paracetamol 
(Nanubolu et and Burley, 2012; Kauffman et al., 2008). 
After determining that all samples crystallized to form II, reference 
samples containing known amounts of form II and the amorphous form were 
prepared. Spectra were analyzed with PCA and the first principal component 
(PC1) was plotted against the reference crystallinity values. There was linear 
correlation between PC1 and crystallinity, which enabled direct use of PC1 




In this section, the first objective of the thesis is addressed. Raman 
spectroscopy and WAXS are compared as methods to monitor crystallization 
in temperatures above Tg. Additionally, the effects of spectral data 
pretreatments on crystallinity quantification were investigated. 
In this section, Raman spectroscopy and WAXS are compared as methods for 
crystallinity determination at temperatures above Tg. There have been many 
studies comparing spectroscopic techniques and X-ray diffraction to 
characterize crystallization below Tg, but studies above Tg are lacking. Priemel 
et al. (2012) reported that x-ray suggested slower crystallization than Fourier 
transform attenuated total reflectance infrared spectroscopy (FT-ATR-IR) 
spectroscopy below Tg. This was due to crystallization being fastest at the 
particle surfaces. FT-ATR-IR measures only the surface of the sample 
(approximately 1-2 μm sampling depth), whereas X-ray analysis samples 
entire particles or even samples (in conventional diffraction setups).  
Mah et al. (2014) reported that during milling crystalline glibenclamide 
became x-ray amorphous, when it was still partly crystalline based on Raman 
spectroscopy. To conclude, Raman spectroscopy was found to be more 
sensitive in detecting small amounts of crystallinity from the amorphous 
samples compared to x-ray. In this case, the difference was attributed to 
Raman spectroscopy being more sensitive to shorter-range order than X-ray 
diffraction analysis. 
These studies illustrate that several measurement factors, including 
sampling depth and different sensitivities to length scales of order, can affect 
quantitative crystallinity measurement, and this section further investigates 
measurement effects, including in samples above Tg. 
Raman spectroscopy is typically considered a surface biased or sensitive 
technique when probing solid pharmaceutical materials due to strong elastic 
scattering the laser light employed and tightly focused laser beams leading to 
relatively small spot sizes. However, in this study the Raman spectrometer 
setup used involved collimated (unfocused) laser light which increases the 
sampling volume, allowing measurements much deeper into the sample. 
Additionally, the beam size is relatively large with a diameter of 6 mm, which 
guarantees good sample representation. 
In the present study, when crystallization of pure amorphous xylitol was 
detected with Raman spectroscopy at a temperature of 20.1-21.6°C, which is 
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clearly above Tg (-24°C), an interesting phenomenon was observed, where the 
spectrum of amorphous xylitol started to undergo a decrease in peak intensity, 
but without new peaks appearing, as one would normally expect in 
amorphous-crystalline transition (Fig. 2). Peak intensities decreased for 25 
min, when no distinct spectral features could be observed. After this, the 
characteristic peaks of crystalline xylitol started to gradually appear. A similar 
phenomenon could be also seen at a temperature of 28.5 – 29.5°C (data not 
presented). When the same sample was inspected visually, it was observed that 
after preparation the sample was opalescent. The sample started gradually to 
become transparent after which the sample gradually turned opalescent again. 
Also Lakio et al. (2015) have reported material turning transparent. This 
phenomenon has been associated with high molecular mobility and particle 
fusion in the rubbery state, i.e. above the glass transition temperature (Slade 
and Levine, 1991; Hancock and Zografi 1997). In the rubbery state the high 
molecular mobility means that crystallization is also likely (Slade and Levine, 
1991; Hancock and Zografi, 1997). 
With the WAXS measurements at 29.0 ± 0.3°C (measurements were not 
performed at the 20.1 – 21.6°C, due to sampling setup limitations), the first 
peaks were seen at 5 min and the intensity increased rapidly (Fig. 3). During 
the experiment, the peak positions did not change, which indicates that the 
unit cell dimensions of crystalline xylitol remained unchanged and there were 
no polymorphic transitions between different crystal polymorphs. 
 
 
Fig. 2. Raman spectra of crystallizing xylitol at 20.1 – 21.6°C. For 0 – 20 min the spectra 
shown are every 4 min and for 20 – 300 min every 10 min. The figure is reproduced from 




Fig. 3. X-ray diffractograms of crystallizing xylitol at 29.0 ± 0.3. Diffraction patterns 
shown were taken every 1 min for 30 min. The figure is reproduced from paper I, with the 
permission of Elsevier. 
 
The WAXS measurement, however, suggested the recrystallization rate of 
amorphous xylitol in the absence of the silica was faster than the 
recrystallization rate of xylitol in the amorphous xylitol-silica dispersion (Fig. 
4), which is the opposite to that observed with the Raman measurements (Fig. 
5a). 
The differences between the Raman spectroscopy and WAXS results can be 
explained by two factors, of which the second one is different to that discussed 
in article I. 
Firstly, when comparing the measurements of xylitol-silica dispersions, the 
Raman spectroscopy results suggest crystallization starts earlier than with the 
WAXS measurements. This can be explained by different sensitivities to 
length-ranges of order. Shorter-range order can be detected with Raman 
spectroscopy, since the technique is sensitive to both intra- and intermolecular 
vibrations. In contrast, WAXS detects longer range order on the order of 
several unit cells. Consequently, Raman spectroscopy is theoretically more 
sensitive to the nucleation and very small nanocrystals, which are present at 
the initial stages of crystallization. 
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Fig. 4. Crystallization of amorphous xylitol (black) and amorphous xylitol in the 
amorphous xylitol-silica mixture (grey) measured with WAXS at 29.0 ± 0.3°C. The figure 
is reproduced from paper I, with the permission of Elsevier. 
 
 
Fig. 5.  Averaged crystallization curves of crystallization of amorphous xylitol alone 
(black) and amorphous xylitol in xylitol-silica mixture (grey) measured using Raman 
spectroscopy in a) ambient conditions (T = 20.1 – 21.6°C and RH% = 21 – 36) and b) 
elevated temperature conditions (T = 28.5 – 29.5°C and RH% = 19 – 25). The figure is 
reproduced from paper I, with the permission of Elsevier. 
 
Secondly, when comparing the onset of xylitol crystallization in pure xylitol 
samples, the crystallization appeared to start earlier with WAXS analysis than 
with Raman analysis. This was not expected based on earlier studies at 
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temperatures below Tg (Ueda et al., 2014; Mah et al., 2014), as well as the 
xylitol-silica mixture results and interpretations (different sensitivities of 
WAXS and Raman to lengths of order) described above. However, the 
differences in crystallinity detected by Raman and WAXS in the pure xylitol 
samples can be explained by the transparency of the samples. With increased 
transparency, fewer Raman scattered photons are directed back to the 
sampling probe and hence detector. Furthermore, the opportunity for Raman 
scattering is decreased due to the lower degree of elastic (back) scattering of 
the laser photons within the sample. So, even though the crystallization could 
have already started, nanocrystals smaller than the wavelength of the light 
would mean that the sample it is not yet opaque and consequently any Raman 
scattering from the small crystals is not sufficiently directed back to the probe 
and detector. It is at this stage, that the overall Raman signal is very weak with 
a lack of visible peaks. Since the effect of opacity (or lack thereof) in the Raman 
signal strength overrides any detection of xylitol crystallization, the Raman 
analysis is not reliable during early crystallization. Thus, only the WAXS 
results are further discussed when comparing the crystallization of xylitol in 
pure xylitol samples and amorphous xylitol-silica dispersions. The Raman 
analyses are more robust in the mixtures, since silica is of a sufficiently large 
particle size (larger than the wavelength of the laser light) that it elastically 
scatters the laser light and keeps the sample opaque.  
Watanabe et al. (2001) have made amorphous indomethacin-silica 
dispersions using melting and quench cooling. In those dispersions, the silicon 
dioxide decreased the crystallization rate by forming interactions between the 
hydroxyl groups of indomethacin and the polar groups of silica. Also, co-
grinding clopidogrel and silicon dioxide made clopidogrel more stable by 
hydrogen bonding between the silanol groups of silicon dioxide and the drug 
molecule (Mártha et al., 2014). Considering the molecular structure, 
molecular bonding between polar groups of silica and xylitol could have 
caused a decreased crystallization rate in the xylitol-silica dispersion in the 
present study (Watanabe et al., 2001; Takeuchi et al., 2005; Xu et al., 2013; 
Mártha et al., 2014).  If the amount of silica used in dispersion is small, as it 
was in the xylitol-silica dispersions in this study, drug loading into pores is 
very limited. However, as mentioned above, interactions between the external 
silica particle surfaces could also stabilize the amorphous form and thus 
explain why the end-state crystallinity of xylitol-silica dispersions is lower than 
in crystallized pure amorphous xylitol.  
To conclude, based on WAXS measurements, the overall crystallization 
rate of xylitol-silica dispersion was decreased over a prolonged period of time 
compared to that of pure xylitol. Additionally, it could be clearly seen that 
Raman spectroscopy is not the most suitable method, when measuring 
samples that exhibit changes in opacity to light in the visible/near-infrared 
wavelength range (in this case, above the sample Tg). 
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This section considers which pre-treatments should be used when performing 
quantitative Raman spectroscopic analysis of xylitol crystallinity in pure 
xylitol samples, as well as in xylitol-silica dispersions. In this study, 36 
pretreatments or pretreatment combinations (including one with no 
pretreatments) were compared based on the accuracy of the PLS model 
created after the treatments. 
Many publications such as those by Fearn et al. (2003), Igne et al. (2010), 
Blanco et al. (2000,2007), Gaydou et al. (2011), Faber et al. (1999), Zhou et al. 
(1998) and Vanarase et al. (2010), have discussed the use of PLS models and 
pretreatments that are beneficial for the accuracy of the models covering a few 
pretreatments and some of them even a few combinations of pretreatments. 
However, these studies have investigated a more limited range of 
pretreatments and their combinations compared to extensive number of 
pretreatments and their combinations presented in figure 6. 
To know if there needs to be separate models for crystallization of xylitol 
alone and in dispersion with silica, the effect of silica on the Raman spectra 
was investigated. Silica did not have significant peaks, but a rather a broad 
area of increased intensity, which is likely caused by fluorescence. 
Additionally, in the spectral region used in the PLS model barely affects the 
shape of the spectra (Fig. 7). Consequently, the effect of silica on the spectra 
could be excluded using baseline correction. Therefore, using a single model 
for both types of Raman spectroscopic samples was justified. 
When the Raman spectra of amorphous and crystalline xylitol were 
compared, overlapping peaks were evident (Fig. 7). Additionally, there were 
baseline and intensity variations, which may have been caused by differences 
in sample packing, density and particle size (Pellow-Jarman et al., 1996; 
Savolainen, 2008). Consequently, peak intensity or area comparison was not 
possibility. It has been reported that multivariate PLS models can have 
significantly smaller root mean square errors than models based on single 
peak heights or areas (Johansson et al., 2005). In addition to selecting 
multivariate analysis to be used in crystallinity determination, extensive work 
was done to discover which pretreatment methods should be done to the 
spectral data before the PLS modelling (Fig. 6). In this thesis, this part of the 
study is presented more widely than in article I, where most of the results in 
this section can be seen. 
To select the best pretreatment or pretreatments to be used, spectra were 
subjected to various pretreatments, the PLS models were constructed and 
their goodness (R2) and predictability (Q2) were compared. The results can be 





Fig. 6. Pretreatment methods for the spectral data. Reproduced from conference paper 
(Palomäki et al., 2016). 
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Fig. 7. Spectra of crystalline xylitol (light grey), amorphous xylitol (dark grey) and 
amorphous xylitol with 10% silica (black). The spectral region is the same as that used in 
the PLS model. 
 
Table 1. Effect of pretreatments on the goodness of model (R2) and its predictability (Q2). 
Reproduced from conference paper (Palomäki et al. 2016). 
 
Pre R2 Q2  Pre R2 Q2 
R1 0.881 0.876  B1 0.932 0.927 
R2 0.281 0.270  B2 0.284 0.275 
R3 0.963 0.963  B3 0.940 0.938 
R4 0.298 0.285  B4 0.292 0.282 
R5 0.294 0.282  B5 0.286 0.272 
R6 0.909 0.904  B6 0.832 0.821 
R7 0.909 0.906  B7 0.866 0.861 
R8 0.971 0.969  B8 0.876 0.871 
R9 0.934 0.928  B9 0.857 0.855 
R10 0.932 0.927  B10 0.932 0.927 
R11 0.880 0.862  B11 0.800 0.793 
R12 0.898 0.895  B12 0.906 0.885 
R13 0.293 0.278  B13 0.270 0.234 
R14 0.293 0.279  B14 0.259 0.222 
R15 0.967 0.966  B15 0.923 0.921 
R16 0.972 0.970  B16 0.931 0.927 
R17 0.279 0.261  B17 0.278 0.251 
R18 0.277 0.230  B18 0.277 0.229 
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Even without pretreatments (Table 1: R1), the PLS model had fairly good 
R2 and Q2 values. Because the baselines were not straight and since there can 
be fluctuations in overall spectral intensity due to measurement artefacts 
unrelated to the sample composition (e.g. laser intensity, sample positioning), 
some preprocessing is preferable. In this study, baseline correction with 
rubberband correction (Table A: B1) and Savitzky-Golay 2nd derivatives (Table 
A: R10) led equally good PLS models. However, if some other additional 
preprocessing was done, Savitzky-Golay 2nd derivatives produced better 
results. The best model was achieved using MSC-correction and Savitzky-
Golay 2nd derivatives (Table A: R16) with R2=0.972 and Q2=0.970. An almost 
equally good model was obtained using SNV-correction, Savitzky-Golay 2nd 
derivatives (Table A: R8) with R2=0.972 and Q2=0.970. Other good models 
(R2>0.95 and Q2>0.95) were obtained using the following pretreatments: MSC 
and Savitzky-Golay 1st derivatives (Table A: R15) having R2=0.967 and 
Q2=0.966 and SNV (Table A: R3) having R2=0.963 and Q2=0.963. 
Since the data had intensity fluctuation and baseline variation, it was not 
surprising that commonly used 2nd derivatives, MSC and SNV were found to 
be good pretreatment methods (Johansson et al., 2005; Strachan et al., 2007; 
Rinnan et al., 2009). The 2nd derivative treatments remove baseline shifts and 
linear trends (Rinnan et al., 2009). The SNV and MSC remove additive and 
multiplicative errors and often produce very similar outcomes. It has to be 
taken in account that MSC requires external reference spectra, which is often 
the average of a calibration set. Even though certain spectral pretreatments 
seemed to be superior to others, it cannot be stated that some of them should 
be exclusively used. In Raman spectroscopy, spectral data can have variations 
caused by fluorescence, particle size, sample packing, instrument 
reproducibility and intensity variation (Heinz et al., 2007; Pellow-Jarman et 
al., 1996), which might affect which pretreatments are preferred for a specific 
measurement set. However, using SNV or MSC with Savitzky-Golay 2nd 
derivatives as pretreatments will mostly lead to good PLS models, provided 
the data itself is of sufficient quality and contains the required information. 
It is important to note the optimal spectral pretreatments were selected 
based on the calibration sets. These samples were prepared by melting and 
quench cooling xylitol and adding a specific amount of crystalline xylitol prior 
to cryo-grinding. The material was ground and liquid nitrogen was evaporated. 
The same samples were also used as the test set (cross-validation). An equally 
important and often challenging additional consideration is any differences 
between the calibration set, and the samples that the model is subsequently 
applied to, in this case, the crystallization samples presented in the previous 
section. While the calibration sets can be considered valid for the opaque 
samples, the changes associated with changing opacity have not been explicitly 
incorporated into the quantitative model development. In this case, the 
changing opacity during crystallization represents a further challenge for the 
development and application of quantitative models, which should be more 
deeply explored in future work.  
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In this section, results regarding the second research objective, involving the 
effect of atmospheric gases on the onset of crystallization of amorphous API, 
are presented. Contrary to the pure xylitol samples in study I, Raman 
spectroscopy is a good method to be used in study (II), since the samples did 
not turn transparent. 
The amorphous samples in article II were first melted and then slowly 
cooled and not ground. Crystallization was monitored using Raman 
spectroscopy and the end state polymorphic form was confirmed using X-ray 
diffraction. According to Raman spectroscopy and WAXS results, these 
amorphous samples subsequently crystallized to form II at all temperatures 
(17.2 ± 0.3°C, 21.7 ± 0.2°C, 23.9 ± 0.4°C and 27.5 ± 0.2°C) and in all 
atmospheres (N2, CO2, dry air and moist air). When amorphous samples were 
prepared similarly and investigated with DSC (Fig. 8), the onset of the Tg was 
22.3 ± 0.1°C, samples started to crystallize at 65.8 ± 0.3°C and the Tm was 
157.8 ± 0.2°C, which indicates, that it had crystallized to form II (Di Martino 
et al., 2000). 
 
Fig. 8. Typical DSC thermograms of a) paracetamol form I reference sample (dark grey, 
dashed), b) amorphous paracetamol (black) and c) paracetamol sample that had 
crystallized during storage (light grey). The figure is reproduced from paper II, with the 
permission of Elsevier. 
 
33 
However, DSC measurements of paracetamol samples that crystallized 
during stability studies (regardless of atmosphere), contradictory to Raman 
spectroscopy and WAXS results, showed a melting peak at 169.0 ± 0.1°C (Fig. 
8), which corresponds to the melting point of paracetamol form I (168 –
 172°C) (Di Martino et al., 1996, 1997, 2000; Nichols and Frampton, 1998). Qi 
et al. (2008) reported a similar phenomenon. In their study, the quench cooled 
sample of paracetamol form II, paracetamol converted into form I during DSC 
measurement in nonisothermal conditions, which was detected with Raman 
spectrometry, but could not be seen in the DSC diffractogram. No exothermic 
recrystallization prior to melting could be seen in the thermogram, which is in 
line with Kauffman et al. (2008) and Di Martino et al. (1996). Kauffman et al. 
(2008) used Raman spectroscopy and DSC simultaneously to measure aging 
of paracetamol form II. In their study, paracetamol converted from form II to 
form I without showing evidence of recrystallization in the thermogram. Di 
Martino et al. (1996) had similar results, when investigating samples, which 
were confirmed to be form II using X-ray, which converted to form I during 
DSC measurement without showing evidence of such a transition in the 
thermogram. Consequently, DSC is not an optimal method for investigating 
polymorphism of paracetamol. 
The effect of headspace gases on onset of crystallization of amorphous 
paracetamol depended on storage temperature (Fig. 9). At 17.2 ± 0.3°C, the 
onset of crystallization of amorphous paracetamol was delayed in dry air 
compared to dry nitrogen or dry carbon dioxide. The higher the temperature 
was, the less obvious the difference between the onset of crystallization was. 
Zografi and Newman (2017) detected that below Tg non-relaxed samples 
absorbed more water than relaxed samples, but they did not detect similar 
behavior above Tg. Any other gas with a tendency to interact with the 
amorphous surface could be expected to interact similarly to water. 
Temperature has an important role in the adsorption of gases onto 
surfaces, dissolution at the surface and diffusion into the matrix. At lower 
temperatures, more adsorption takes place. Additionally, the solubility of 
gases in solids is higher at lower temperatures (Chaix et al., 2014). According 
to the Stokes-Einstein equation, the diffusion coefficient is directly 
proportional to temperature and inversely proportional to size of the gas 
molecules and viscosity of the amorphous matrix. A higher temperature would 
increase molecular motion and reduce viscosity. This would lead to increased 
molecular mobility and diffusion of the gas from the surface to the bulk. This 
may reduce build-up of the gases on the surface of the glassy matrix. Since the 
recrystallization is more surface-driven below Tg and a lower viscosity of the 
surface compared to bulk is needed for surface-biased crystallization (Yu et al. 
2016), temperature may play a key role in solid-gas interactions of amorphous 
systems. Indications of this were also seen in the present study (Fig. 9), where 
the changes in dry gaseous environment were found to have a more 
pronounced effect on crystallization at lower temperatures. 
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Fig. 9. Average onset of crystallinity for paracetamol in different temperatures and 
atmospheres. The figure is reproduced from paper II, with the permission of Elsevier. 
 
At the Tg and above, amorphous material becomes a super-cooled liquid, in 
which surface crystallization is less dominant over bulk crystallization. This is 
consistent with no difference being seen in crystallization onset times between 
different atmospheres above Tg. At the highest temperature at 27.5 ± 0.2°C in 
all atmospheres, except in moist air, lag times were not constant and the 
crystallization rates had multiple phases where the crystallization rates 
fluctuated. In all other environments, crystallization followed a typical 
sigmoidal curve with one period of increasing crystallization rate, steady state 
of crystallization rate and one period of decreasing crystallization rate. 
Additionally, there was notable variation between samples, which is also 
consistent with observations by Yu et al. (2016), in which crystallization 
kinetics of amorphous materials were found to vary between samples at 
temperatures above Tg to that below Tg (Fig. 9). 
In this study, paracetamol crystallized faster in humid air compared to dry 
air. Amorphous materials are hygroscopic and are plasticized by humidity 
resulting in a lower Tg and higher molecular mobility (Hancock and Zografi 
1994). As a result, when relative humidity rises, the crystallization rate also 
increases (Lehmkemper et al., 2017; Hoppu et al., 2007). Still, differences in 
moisture content cannot explain the differences in crystallization onset 
between dry air and other dry atmospheres, when the amount of water in gas 
and collisions to sample surfaces are considered (Table 2). Additionally, no 
effect of humidity on crystallization rate of dry samples was seen in the Avrami 
constant n, when crystallization curves were fitted with Avrami equation. 
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Consequently, water alone does not explain the difference in crystallization 
onset times of amorphous paracetamol in dry air and nitrogen. 
 
Table 2. Amount of water in various gas mixtures and collision frequency of water 
molecules. Calculations assume a temperature of 20°C and normal atmospheric pressure. 
The table is reproduced and edited from paper II, with the permission of Elsevier. 
 
Atmosphere RH% H2O 
(g/m3) 
H2O (m/m-%) in 
the atmosphere 
Theoretical amount of 
collisions between 
gaseous H2O molecules 
and the sample surface 
(n/Å2/s)a 
Air 4.4-4.7 0.76-0.81 0.06 4200-4400 
CO2 1.2-1.5 0.21-0.26 0.02 1100-1400 
N2 ≤0.1 ≤0.2 0.0 ≤ 100 
Humid air 21.2-22.2 3.67-3.85 0.29-0.30 20000-21000 
a Collision frequency (Atkins 1998, Jensen 2007) 
 
Amorphous materials and gases may interact with each other via 
intermolecular interactions (Byrn et al., 2001; Buckton and Gill, 2007; Manca 
et al., 2003), so the assumption of pure Fickian penetrant diffusion of gases is 
invalid in the present study. Attractive interactions between gas and molecules 
in amorphous substance would lead to accumulation of gas molecules in the 
surface layers of the sample. 
It has been shown, that amorphous and liquid paracetamol have hydrogen 
bonds between the phenolic hydroxyl and amine groups and between the 
phenylic hydroxyl and carbonyl oxygen (Gunawan et al., 2006). Hydrogen 
bonding even has an effect on the structural relaxation of the glass (Gunawan 
et al., 2006). Additionally, if stronger hydrogen donors or acceptors interfere 
with hydrogen bonds between paracetamol molecules, the amount of crystal 
nuclei formation is reduced (Trasi and Taylor 2012). Since at the surface there 
are functional groups that are in contact with the gas phase and are not 
interacting with functional groups of the other molecules, one could assume 
that the molecules could interact with headspace gas molecules, and these 
interactions could potentially have an effect on crystallization. The results of 
this study support this hypothesis. 
On the sample surface, amorphous paracetamol molecules are more 
randomly arranged than with a crystalline substance (though there may be 
some short-range order) and various functional groups are presented to the 
gaseous phase. It can be assumed that amine, phenolic hydroxyl and carbonyl 
oxygen, that have tendencies to form molecular bonds, would interact 
especially with O2 and also with N2. N2 is less reactive due to the triple bonding 
compared to O2 with double bonding. Interacting gas molecules adsorbed on 
to the surface layer may slow down nuclei formation and consequently, cause 
a delay in the onset of crystallization. This is supported by Manca et al. (2003), 
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who found that N2 and CO2 were adsorbed site-specifically onto the surface of 
amorphous ice. Since these kinds of interactions cannot be detected using 
Raman spectroscopy, it was not possible to get direct evidence of similar site-
specific bonding in the present study, but the phenomenon cannot be 
excluded. 
There was some variation between onsets of crystallization between similar 
samples in the present study. They may have had some spatial and dynamic 
heterogeneity (Ediger, 2000, Sillescu 1999), which would lead to differences 
in the time required for stable nuclei to form and would, consequently, cause 
variation in lag-time before the onset of crystallization. In the present study, 
such heterogeneous nucleation occurred at the gas-amorphous-glass slide 
interface as described in section 5.1.3. 
To conclude, physisorption is known to occur more at low temperatures 
through intermolecular interactions at active sites. As the temperature is 
decreased, adsorption and dissolution of gases into the amorphous material 
increase while the decrease in temperature makes the material become more 
viscous in the bulk compared to the surface. When, at the same time, also the 
tendency of surface crystallization increases, it can be summarized that the 
onset of crystallization of amorphous paracetamol is expected to be affected 
by atmospheric gases below Tg, as shown in the present study. Above Tg a 
similar effect was not seen. 
In this section, the third research objective, which considers the effect of 
excipients on crystallization of two-phase amorphous solid dispersions, is 
addressed. The section explores potential stabilization with two-phase systems 
in more detail from a mechanistic perspective.  
In study I, silica was added to influence the crystallization of amorphous 
xylitol. In this case, the silica is not expected to mix with the xylitol on a 
molecular/atomic level, and thus the two phases (silica and xylitol) can be 
considered chemically pure. Furthermore, the silica is effectively physically 
stable in the amorphous form and not liable to crystallization itself.  
Crystallization of xylitol could be affected by mechanical inhibition of crystal 
growth and molecular interactions at the xylitol-silica interfaces. In study III, 
both API and excipient are small molecules, and both materials are liable to 
crystallization. In this case, in addition to mechanical inhibition of 
crystallization and molecular interactions at the phase interfaces, there can be 
some API molecules in the excipient-rich phase and vice versa in a two-phase 
system (resulting in API-rich areas and excipient-rich areas). Consequently, 
there is some level of molecular level mixing, which can further inhibit 
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crystallization. In addition, crystallization of either component could 
subsequently influence crystallization of the other component.  
As mentioned above, the first two-phase solid dispersion system 
investigated included xylitol and non-ordered mesoporous silica, in which 
only the xylitol was expected to crystallize (I). In the study, pure xylitol 
crystallized faster than the xylitol-silica solid dispersion (based on WAXS 
analysis, since Raman was not suitable for analysis of the pure xylitol). These 
results have already been presented in section 5.1.1. Qualitative differences in 
xylitol samples before and after crystallization were explored in this section 
with polarizing light microscopy and DSC. 
In the polarizing light microscopy images (Fig. 10), the crystallite size 
appeared much smaller in the solid dispersion than in xylitol alone. It appears 
that the presence of the silica prevented larger crystals from growing, which is 
consistent with the lower crystallization rate of xylitol in the xylitol-silica 
dispersion compared to xylitol alone. 
DSC can offer insights into whether the molecular mobility of the xylitol is 
affected by the presence of the mesoporous silica. In the DSC measurements 
in article I, amorphous xylitol and amorphous xylitol-silica dispersions 
showed a Tg for amorphous xylitol (Fig. 11). The onset of the Tg for xylitol was 
at -23.3°C, which is well in line with earlier findings of Talja and Roos (2001), 
in which the stated Tg of waterless xylitol was -24°C. The slight difference is 
likely due to different heating rates. The Tg was followed by a wide exothermic 
peak corresponding to recrystallization of amorphous xylitol and sharp 
endothermic melting peak (92 – 96°C). 
The onset of Tg for xylitol in the xylitol-silica dispersion was -32°C, which 
is significantly lower than the Tg of xylitol alone. Additionally, the glass 
transition occurred over a larger temperature range than with pure xylitol. 
Talja and Roos (2001) have earlier reported that water content significantly 
affects the Tg of xylitol (as would be expected due to water being a plasticizer), 
and xylitol samples containing 10% of moisture had Tg of -53°C. 
Hygroscopicity of silica explains lowering of the Tg compared to pure xylitol, 
which would promote crystallization. Amorphous sucrose has previously been 
stabilized using micro-sized filler particles (Hellrup and Mahlin, 2011). 
However, the stabilizing effect of the microparticles was lost, when the relative 
humidity exceeded a critical threshold. As mentioned above, any moisture in 
the sample would act as a plasticizer, and thus increase molecular mobility and 
counteract the stabilizing effect of silica (Andronis et al., 1997; Hellrup and 
Mahlin, 2011). However, in the present study with xylitol, this effect appears 
to be more than compensated for by the potential interface interactions 
between silica and xylitol and/or steric hindrance, since silica slows down 
crystallization according to WAXS. 
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Fig. 10. Polarizing light microscope images of ground a) xylitol and b) xylitol-silica 
dispersion after crystallization of xylitol. The figure is reproduced and edited from paper 






Fig. 11. Typical DSC thermograms of mixture of amorphous xylitol and silica (light grey), 
amorphous xylitol (black) and crystalline xylitol (dark grey, dashed). The figure is 
reproduced from paper I, with the permission of Elsevier. 
 
In article III, paracetamol was mixed with another small molecule, either 
trehalose or melibiose, resulting in two-phase amorphous systems, as revealed 
with XRPD. Two small molecule components would theoretically allow some 
degree of molecular-level mixing upon melting. Despite this, any mixing was 
limited, as evidence of the two-phase nature was provided by both FTIR and 
DSC.  
When FTIR results of the amorphous solid dispersions of paracetamol-
melibiose or paracetamol-trehalose were compared to predicted spectra 
calculated from the weighted average of the amorphous paracetamol spectrum 
and either amorphous melibiose or trehalose, the spectra were almost 
identical. This indicates that the solid dispersions lacked significant drug-
excipient intermolecular interactions, such as H-bonding, and may have 
existed as two-phase systems.  
The two-phase nature was confirmed with DSC. With both the amorphous 
paracetamol-trehalose and paracetamol-melibiose dispersions, there were 
two Tgs instead of one (Table 3). The first Tg, at 17.9 ± 0.5°C, corresponded to 
that of the paracetamol-rich phase and the second Tg to those of the excipient-
rich phases. This paracetamol-rich phase Tg is lower than that of the pure drug, 
in contrast to what would be expected upon any mixing with either excipient 
according to Gordon-Taylor behavior. The Tg is lowered likely because of the 
hygroscopicity of melibiose and trehalose, and thus water absorption into the 
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system. Even though samples were amorphized in a nitrogen atmosphere, the 
humidity getting into contact with sample upon rapid cooling of the melt with 
liquid nitrogen and also DSC sample preparation could not be totally 
prevented. 
 
Table 3. Endo- and exothermic reactions in DSC measurements (n=3,  ± sd). 
 









Amorphous paracetamol 24.7±0.2 57.5±0.7 171.7±0.3 
Amorphous melibiose 88.5±0.2 NA NA 
Amorphous trehalose 117.5±1.0 NA NA 
Crystalline paracetamol NA NA 171.3 
Crystalline melibiose NA NA 189.1 
Crystalline trehalose NA NA 213.4 
Solid dispersion: paracetamol 




Solid dispersion: paracetamol 








In the paracetamol-trehalose and paracetamol-melibiose dispersions both 
Tgs corresponding to the disaccharides, melibiose and trehalose, were also 
lowered compared to the Tgs of the pure excipients (without paracetamol) 
right after preparation. This is likely to be caused by the sugars’ tendency to 
absorb water during storage, especially in the amorphous phase (Hancock and 
Dalton 1999), which would lower the Tg remarkably (Liu et al., 2006; Schebor 
et al., 2010). Additionally, since the Tg of paracetamol (in this study 17.9 ± 0.5 
°C) is lower than those of trehalose or melibiose, and there may have been 
some limited mixing of the components, which would further serve to lower 
the Tgs (according to Gordon-Taylor behavior). 
Even though there were two Tgs in each dispersion and thus two phases 
were present, the onsets of crystallization in the DSC thermograms for 
paracetamol in the dispersions were remarkably different compared to that of 
paracetamol alone (without any excipient). Amorphous paracetamol alone had 
an onset of recrystallization at 57.5 ± 0.7°C, while in the paracetamol-
melibiose mixtures it crystallized at 117.2 ± 1.2°C and in the paracetamol-
trehalose mixtures it crystallized at 135.7 ± 2.7°C. These findings are 
consistent with the storage study results. It is interesting to note, that there 
was only a single crystallization exotherm in the thermograms, despite two 
phases existing. However, crystallization exotherms were not present in the 
thermograms for trehalose or melibiose in pure form. 
These two-phase systems were subjected to accelerated stability testing 
conditions, with a relative humidity of 75% and temperature of 38 ± 0.5°C. The 
sample crystallization was detected using WAXS and it was seen that samples 
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crystallized to paracetamol form I. Crystallinity was determined by peak 
heights at 9.8° 2θ for crystalline melibiose, 14.6° for trehalose dihydrate and 
18.2° for paracetamol form I. Ground pure amorphous paracetamol 
crystallized immediately, while the two disaccharides crystallised more slowly, 
with onsets of crystallization of 3 hours for trehalose and more than 6 hours 
for melibiose (Figure 12). 
 
 
Figure 12. Crystallization of a) amorphous paracetamol alone (black circles), amorphous 
trehalose alone (red squares), amorphous paracetamol in paracetamol-trehalose solid 
dispersion (black, triangles) and amorphous trehalose in paracetamol-trehalose solid 
dispersion (red, triangles) and b) amorphous paracetamol alone (black circles), 
amorphous melibiose alone (blue squares), amorphous paracetamol in paracetamol-
melibiose solid dispersion (black, triangles) and amorphous melibiose in paracetamol-
melibiose solid dispersion (blue, triangles). Samples crystallizing were stored at a relative 
humidity of 75 ± 1% and temperature of 38 ± 0.5°C. 
 
While neither trehalose nor melibiose postponed the onset of 
crystallization of paracetamol, they did slow its rate of crystallization — 
substantially in the case of melibiose. In turn, there was some indication that 
the crystallization of paracetamol itself may have catalyzed the crystallization 
(nucleation and/or crystal growth) of the disaccharides, though this effect, if 
present, was much smaller than the stabilizing effect of the two-phase solid 
dispersions on the less stable paracetamol. These results suggest that, solid 
dispersions involving two small molecule compounds, even in the case of two-
phase systems, can stabilize the less stable amorphous component.  
These observations occurred with the samples exposed to accelerated 
stability testing conditions (38 ± 0.5°C, 75 ± 1% RH), where the amorphous 
samples were most likely in the rubbery state. In contrast, at a relative 
humidity of 3 ± 1% and temperature of 38 ± 0.5°C, in which the samples are 
expected to be present mainly in the glassy state, no sign of crystallization 
could be seen in amorphous samples of paracetamol-trehalose and 
paracetamol-melibiose in any of the samples in 356 days (data not shown), 
whereas (based on article II) pure paracetamol alone can stay amorphous in 
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dry conditions at the temperature of 16.9 – 27.7°C only for some hours (Fig. 
9). 
Semjonov et al. (2017) have earlier stated that two-phase system can slow 
down crystallization. They state that in addition to the level of miscibility 
(which affects the relative concentrations of the other component in the drug- 
and excipient-rich phases), steric hindrance and reduction of molecular 
mobility at interfaces may have a significant role in the stabilization of 
amorphous material in two-phase systems. The findings in this thesis are 
consistent with this reasoning, and since trehalose and melibiose had higher 
Tgs (97.1 ± 0.4°C and 79.8 ± 0.9°C) than paracetamol (17.9 ± 0.5°C) in solid 
dispersions, molecular mobility reduction at the interfaces is expected to play 
key role in the stabilization of amorphous paracetamol in solid dispersions 
with trehalose and melibiose. To conclude, two-phase solid dispersions can 
slow down crystallization rate and/or postpone crystallization remarkably. 
Usage of the two-phase systems for stabilizing amorphous systems is expected 
to become more common in the future. Even though they might be less 
effective as stabilizers of the amorphous form, they form weaker 
intermolecular bonds and consequently, may not inhibit drug dissolution as 




In the present thesis, new information about the effect of excipient and gas 
interactions on the onset of crystallization and crystallization processes of 
amorphous materials was obtained. Such insights are crucial, due to the 
increasing importance of amorphous materials in pharmaceutical field. 
In article I, it was found that introducing 10% (m/m) of non-ordered 
mesoporous silica to amorphous xylitol decreased the overall crystallization 
rate of amorphous xylitol. It was found that Raman spectroscopy is not a 
suitable method for crystallinity detection if the transparency of the sample 
changes, as is prone to happen at temperatures above Tg. The article also 
demonstrated more in depth than earlier have been reported, the importance 
of usage of carefully selected spectral pre-treatments prior to multivariate 
analyses. 
In article II, the onset of crystallization in different atmospheres was 
investigated. It was found that at temperatures below Tg, storing amorphous 
paracetamol samples in dry air delayed the onset of crystallization when 
compared to samples stored in pure nitrogen. The results imply that oxygen, 
the gas with reactive nature, was adsorbed onto the surface of the amorphous 
paracetamol and led to disturbance of the intermolecular interactions between 
paracetamol molecules. Headspace gases can have a more significant effect on 
the stability of amorphous pharmaceuticals than previously reported. 
In article III, two small molecule excipients, trehalose and melibiose, 
slowed down the crystallization of amorphous paracetamol significantly, when 
mixed with the drug in a two-phase solid dispersion and stored in elevated 
temperature and humidity conditions. DSC and FTIR provided evidence that 
the components exhibited very limited mixing on a molecular level, but despite 
this, crystallization of the less stable amorphous component was inhibited. 
Additionally, in some cases two-phase systems could be more useful. Two-
phase systems have weaker bonds compared to one-phase systems and 
consequently, might not inhibit dissolution to a similar degree as stronger 
intermolecular interactions can in some cases. 
Overall, these studies demonstrate that crystallization of material can be 
interrupted by contact with other molecules, with or without mixing on the 
molecular level. Thus, while strong bonds between different molecules have 
long been established as a stabilizing mechanism, these studies show that 
interactions at interfaces in two-phase systems can also substantially influence 
crystallization, even without any degree of molecular-level mixing. 
Furthermore, as the effect of gas on crystallization of amorphous material 
suggested, also non-specific interactions can affect crystallization. 
Crystallization is a process that has been extensively studied, but there are 
still areas that remain challenging with respect to understanding how different 
formulation and environmental factors affect crystallization. While this thesis 
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has provided further insight into these factors, more research is needed to 
ensure that amorphous materials can be used effectively and safely more often 
in drug formulations in the future. 
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